LTTS2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member LTTS2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue01Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue02Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue03Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue04Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue05Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue01Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue02Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue03Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue04Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue05Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults01Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults02Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults03Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults04Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults05Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults01Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults02Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults03Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults04Member LTTS2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults05Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets01Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets02Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets03Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets04Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets05Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities01Member LTTS2021-12-31in-bse-fin:OneReportableSegmentLiabilities01Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities02Member LTTS2021-12-31in-bse-fin:OneReportableSegmentLiabilities02Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities03Member LTTS2021-12-31in-bse-fin:OneReportableSegmentLiabilities03Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities04Member LTTS2021-12-31in-bse-fin:OneReportableSegmentLiabilities04Member LTTS2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities05Member LTTS2021-12-31in-bse-fin:OneReportableSegmentLiabilities05Member LTTS2021-10-012021-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LTTS2021-10-012021-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LTTS2021-10-012021-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LTTS2021-10-012021-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LTTS 2021-04-01 2022-03-31 2022-01-03 INR Millions Third quarter Multi segment 2021-10-01 2021-12-31 Unaudited Standalone 15056000000.00 372000000.00 15428000000.00 0.00 0.00 0.00 8080000000.00 99000000.00 457000000.00 3491000000.00 12127000000.00 3301000000.00 0.00 3301000000.00 856000000.00 16000000.00 872000000.00 0.00 2429000000.00 0.00 0.00 0.00 0.00 2429000000.00 454000000.00 2883000000.00 0.00 0.00 211000000.00 2 23.05 23.00 0.00 0.00 23.05 23.00 Explanatory notes to the statement of standalone unaudited financial results for the quarter and nine months ended December 31, 2021 1. The standalone unaudited financial results for the quarter and nine months ended December 31, 2021 been taken on record by the Board of Directors at its meeting held on January 18, 2022. The statutory auditors have carried out limited review of the above standalone unaudited financial results and have issued an unqualified limited review report. The results for quarter and nine months ended December 31, 2021 are extracted from the unaudited interim standalone financial statements. These standalone interim financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended. 2. During the quarter and nine months ended December 31, 2021, the Company has allotted 3,06,645 and 4,39,624 equity shares of Rs. 2 each fully paid-up respectively on exercise of stock options by employees, in accordance with the Company's stock option scheme. 3. Estimation uncertainty relating to COVID-19: The Company has considered internal and certain external sources of information including reliable credit reports, economic forecasts and industry reports up to the date of approval of the financial results in determining the impact on various elements of its financial results. The Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on current estimates, the Company expects to fully recover the carrying amount of trade receivables including unbilled receivables, intangible assets and investments. Management of the Company has also reviewed goodwill and is of the opinion that no impairment is required at present. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results. 4. The Board of Directors at its meeting held on January 18, 2022, has declared an interim dividend of Rs.10 per equity share. 5. Figures for earlier periods have been regrouped, wherever necessary. Multi segment 2021-04-01 2021-12-31 Unaudited Standalone 43256000000.00 1118000000.00 44374000000.00 0.00 0.00 0.00 23742000000.00 298000000.00 1372000000.00 9772000000.00 35184000000.00 9190000000.00 0.00 9190000000.00 2444000000.00 -20000000.00 2424000000.00 0.00 6766000000.00 0.00 0.00 0.00 0.00 6766000000.00 844000000.00 7610000000.00 0.00 0.00 211000000.00 2 64.33 64.17 0.00 0.00 64.33 64.17 Other expenses 3491000000.00 Other expenses 9772000000.00 Industrial Products 3205000000.00 Medical Devices 1962000000.00 Plant Engineering 2551000000.00 Telecom & Hitech 2704000000.00 Transportation 4634000000.00 Industrial Products 9290000000.00 Medical Devices 5638000000.00 Plant Engineering 7331000000.00 Telecom & Hitech 7901000000.00 Transportation 13096000000.00 15056000000.00 43256000000.00 0.00 0.00 15056000000.00 43256000000.00 Industrial Products 929000000.00 Medical Devices 623000000.00 Plant Engineering 624000000.00 Telecom & Hitech 498000000.00 Transportation 864000000.00 Industrial Products 2844000000.00 Medical Devices 1771000000.00 Plant Engineering 1687000000.00 Telecom & Hitech 1323000000.00 Transportation 2434000000.00 3538000000.00 10059000000.00 99000000.00 298000000.00 138000000.00 Notes for segment information a Segments have been identified in accordance with Indian Accounting Standards ( Ind AS ) 108 on Operating Segments, considering the risk/return profiles of the business, their organisational structure and internal reporting systems. bProperty, plant and equipment used and liabilities contracted for performing the Company's business have not been identified to any of the above reported segments as the property, plant and equipment and services are used interchangeably among segments. 571000000.00 3301000000.00 9190000000.00 Industrial Products 0.00 Medical Devices 0.00 Plant Engineering 0.00 Telecom & Hitech 0.00 Transportation 0.00 0.00 Industrial Products 0.00 Medical Devices 0.00 Plant Engineering 0.00 Telecom & Hitech 0.00 Transportation 0.00 0.00